ANXA2 also contributes to therapeutic resistance of multiple malignancies, such as nasopharyngeal carcinoma, gastric cancer, breast cancer and pancreatic cancer by mediating various signaling pathways including p38MAPK/Akt and PI3K/Akt/NF-kB pathways (Takano et al., 2008; Gong et al., 2010; Zhang et al., 2014a; Zhang et al., 2014b; Chen et al., 2015). This evidence concerns the gene AKT1 and gastric cancer.